Incidentaloma screening: Difference between revisions

Jump to navigation Jump to search
Usama Talib (talk | contribs)
Created page with "__NOTOC__ {{Incidentaloma}} {{CMG}}; {{AE}} ==Overview== There is insufficient evidence to recommend routine screening for [disease/malignancy]. OR According to the [guid..."
 
Medhat (talk | contribs)
No edit summary
Line 5: Line 5:
==Overview==
==Overview==


There is insufficient evidence to recommend routine screening for [disease/malignancy].
According to the [guideline name], screening for [disease name] is not recommended.
==Screening==
*According to the European Society of Endocrinology Clinical Practice Guideline, screening for adrenal incidentaloma includes:


OR
=== Indications for adrenal incidentaloma screening ===
* Patients with possible autonomous cortisol secretion or autonomous cortisol secretion for hypertension and type 2 diabetes mellitus.
* Patients with asymptomatic vertebral fractures.
* Screening imaging in patients with a hereditary syndrome leading to adrenal tumors.
* Family screening with 1 mg dexamethasone test can be considered in cases of bilateral macronodular hyperplasia, especially in younger patients.


According to the [guideline name], screening for [disease name] is not recommended.
=== Screening measures ===
{| class="wikitable"
!Disease
!Laboratory tests
|-
|Pheochromocytoma
|'''24-hour urine:'''
Fractionated
 
metanephrines
 
Fractionated
 
catecholamines
 
'''Blood:'''
 
Fractionated
 
metanephrines
|-
|Cushing's
syndrome
|'''For patients with'''
'''symptoms of Cushing's'''
 
'''syndrome:'''
 
24-hour urinary free
 
cortisol
 
'''For patients lacking'''
 
'''symptoms of Cushing's'''
 
'''syndrome:'''
 
1 mg overnight


OR
dexamethasone


According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].
suppression test
==Screening==
|-
|Primary
aldosteronism
|Plasma aldosterone
concentration, plasma


*There is insufficient evidence to recommend routine screening for [disease/malignancy].
renin activity
OR
|}
*According to the [guideline name], screening for [disease name] is not recommended.
OR
*According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with:
**[Condition 1]
**[Condition 2]
**[Condition 3]


==References==
==References==

Revision as of 17:56, 30 August 2017

Incidentaloma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Incidentaloma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Incidentaloma screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Incidentaloma screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Incidentaloma screening

CDC on Incidentaloma screening

Incidentaloma screening in the news

Blogs on Incidentaloma screening

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Incidentaloma screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

According to the [guideline name], screening for [disease name] is not recommended.

Screening

  • According to the European Society of Endocrinology Clinical Practice Guideline, screening for adrenal incidentaloma includes:

Indications for adrenal incidentaloma screening

  • Patients with possible autonomous cortisol secretion or autonomous cortisol secretion for hypertension and type 2 diabetes mellitus.
  • Patients with asymptomatic vertebral fractures.
  • Screening imaging in patients with a hereditary syndrome leading to adrenal tumors.
  • Family screening with 1 mg dexamethasone test can be considered in cases of bilateral macronodular hyperplasia, especially in younger patients.

Screening measures

Disease Laboratory tests
Pheochromocytoma 24-hour urine:

Fractionated

metanephrines

Fractionated

catecholamines

Blood:

Fractionated

metanephrines

Cushing's

syndrome

For patients with

symptoms of Cushing's

syndrome:

24-hour urinary free

cortisol

For patients lacking

symptoms of Cushing's

syndrome:

1 mg overnight

dexamethasone

suppression test

Primary

aldosteronism

Plasma aldosterone

concentration, plasma

renin activity

References

Template:WH Template:WS